A Phase 1/2 interventional study of ASKB589 +CAPOX+Sintilimab/Tislelizumab in Gastric Cancer and Gastroesophageal Cancer (GC), sponsored by AskGene Pharma, Inc.. Active, not recruiting at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-10.
Sponsored by AskGene Pharma, Inc. (part of Beijing Aosaikang Pharmaceutical Co., Ltd.) · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing sintilimab in Stomach Neoplasms — 29 open to participants now, 35 under way, 2 of them phase 3. sintilimab · Stomach Neoplasms.
Among the 44 studies testing sintilimab in Stomach Neoplasms, this one is the 10th largest by enrollment, is one of 9 that started in 2023, is one of 3 in phase 1/2, reaches primary completion later than 12 of the 34 other live ones, and was the 16th registered.
3,403 studies on the registry are indexed under Stomach Neoplasms; 995 are open to participants now.
Browse Stomach Neoplasms studies →29 of the 44 studies testing sintilimab in Stomach Neoplasms are open now, in 1 country. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18+
Fudan University · Sites in China
Ages 18–70
Zuoyi Jiao · Sites in China
Ages 18–75
Sichuan Luzhou Buchang Biopharmaceutical Co., Ltd. · Sites in China
Ages 18–75
West China Hospital · Sites in China
Ages 18–75
By country, each count listing its studies:
No approval found in the FDA or EMA files read. How studies give it is on its page →
Of the 704 Stomach Neoplasms studies recruiting now, 376 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 28 take children under 18; 69 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 41 · Phase 3 4
First in 2018; this study’s year is marked. 9 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 62 is close to the median of 66 across 2,502 interventional studies indexed under Stomach Neoplasms.
Median enrollment 40 across the 44 interventional studies. Of the 1 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under AskGene Pharma, Inc., one of the names counted as Beijing Aosaikang Pharmaceutical Co., Ltd.. Under that name alone:
AskGene Pharma, Inc. is the lead sponsor of 5 studies on the registry; 1 is open to participants now.
Beijing Aosaikang Pharmaceutical Co., Ltd. has 1 study filed under Stomach Neoplasms — fewer than ten, so there is no comparison to draw.
4 of the studies testing sintilimab in Stomach Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06742411West China HospitalXELOX Combined With Sintilimab and HBO for Advanced or Metastatic GC/GEJC | 2026-12-31 |
| NCT06555471The First Affiliated Hospital with Nanjing Medical UniversityA Single-arm, Phase II Exploratory Study of Sintilimab in Combination With Chemoradiotherapy in Elderly Patients With Locally Advanced Gastric Cancer | 2026-12-31 |
| NCT07658872Sichuan UniversityPerioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma | 2027-05-19 |
| NCT07669740The First Affiliated Hospital with Nanjing Medical UniversityA Study on the Efficacy and Safety of Sintilimab Combined With Ramucirumab and Paclitaxel in the Treatment of Gastric Cancer Patients With Short-term Recurrence After Adjuvant Therapy | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 44 studies testing sintilimab in Stomach Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This was an open-label, phase 1/2 study to evaluate safety, tolerability, pharmacokinetics, and antitumor activity of ASKB589 in combination with CAPOX and PD-1 inhibitors in first-line treatment of patients with locally advanced, recurrent, or metastatic gastric and esophagogastric junction adenocarcinoma.
A two-part, dose-escalation and expansion study of ASKB589 was initiated to determine the MTD, PK, PD, and efficacy in combination with chemotherapy and PD-1 inhibitors.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Line of therapy
A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.
“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HER2
HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.
In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
PD-1, PD-L1 and checkpoint inhibitors
PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.
PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years. ASKB589 is administered intravenously at a fixed dose. the drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years.
Drug: ASKB589 +CAPOX+Sintilimab/Tislelizumab
Drug pages: Omectatug · Sintilimab · Tislelizumab
Oxaliplatin: intravenous infusion, 130mg/m2, infusion for more than 3h, every 3 weeks for a cycle, infusion 6 cycles; Capecitabine: oral administration, 1000mg/m2, 2 times, 14 days, 7 days rest, every 3 weeks for a cycle; Sintilimab/Tislelizumab was administered intravenously at 200mg. The drug was administered once every 3 weeks, and the longest cumulative duration was 2 years. ASKB589 is administered intravenously at a fixed dose. The drug was given once every 3 weeks for a cycle, with the longest cumulative duration of 2 years.
Number of participants with adverse events as assessed by CTCAE v5.0
An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who experience an AE will be presented.
Time frame: up to 21 days following last dose
The incidence and case number of DLT (Dose Limiting Toxicity) during observation period.
DLT is short for Dose Limiting Toxicity,dose-limiting describes side effects of a drug or other treatment that are serious enough to prevent an increase in dose or level of that treatment.
Time frame: up to 21 days following last dose
Maximum Tolerated Dose (MTD)
The MTD was defined as the highest dose of ASKB589 not causing DLT in more than 33% of patients in the first treatment cycle.
Time frame: up to 21 days following last dose
The recommended dose
The recommended dose will be determined during the dose escalation and dose expansion stage of the study.
Time frame: from date of treatment start until data cut-off, up to 2 years
Pharmacokinetics:maximum Plasma Concentration [Cmax]
Serum samples will be collected for Cmax analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics:time to maximum observed plasma concentration (Tmax)
Serum samples will be collected for Tmax analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics:elimination rate constant(Kel)
Serum samples will be collected for Kel analysis
Time frame: Up to 21 days after injection
Pharmacokinetics:terminal elimination half life (T1/2)
Serum samples will be collected for T1/2 analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics:apparent volume of distribution (Vz/F)
Serum samples will be collected for Vz/F analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics:Area Under Curve (AUC)
Serum samples will be collected for AUC analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics: Mean ResidenceTime(MRT)
Serum samples will be collected for MRT analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics: plasma clearance rate (CL)
Serum samples will be collected for CL analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics: steady-state peak concentration (Css_max)
Serum samples will be collected for Css\_max analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics: time to steady-state peak concentration (Tss_max)
Serum samples will be collected for Tss\_max analysis.
Time frame: Up to 21 days after injection
Pharmacokinetics: minimum value of steady plasma drug concentration(Css_min)
Serum samples will be collected for Css max analysis.
Time frame: Up to 21 days after injection
Evaluation of immunogenicity
Incidence of anti-drug antibodies (ADA)
Time frame: from date of treatment start until data cut-off, up to 2 years
Objective response rate(ORR)
Evaluation of objective response rate assessed by RECIST 1.1
Time frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
disease control rate(DCR)
Evaluation of Disease control rate assessed by RECIST 1.1
Time frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
Duration of Response(DOR)
Duration of response assessed by RECIST 1.1
Time frame: from date of treatment start until disease progression,date of death or withdrawal from study,whichever came first, up to 2 years
Progression free survival(PFS)
Progression of tumor will be measured by RECIST v1.1
Time frame: from date of treatment start until the date of disease progression or until death due to any causes, up to 2 years
Overall survival(OS)
defined as the time from the date of treatment start until date of death due to any cause.
Time frame: from the date of treatment start until the documented date of death from any cause,up to 2 years.
Started Feb 2023 (actual). Primary completion is estimated for Oct 2025, 32 months after the start.
Of 89 industry-sponsored phase 1/2 interventional studies under Stomach Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 41 and three quarters within 109. This study's planned 32 months is below that.
Counting every sponsor, half of 156 studies reached it within 60 months; a quarter within 41 and three quarters within 109.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Omectatug · Sintilimab · Tislelizumab